ANI Pharmaceuticals Completes $210m Novitium Acquisition
Acquisition Expected To Bolster R&D, Generics Scale And CDMO Business
ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.
You may also be interested in...
ANI Pharmaceuticals and Eton Pharmaceuticals have announced the launch of their Carbaglu rival, with the companies having been granted a Competitive Generic Therapy designation by the FDA, along with 180 days of related exclusivity. ANI has also announced receiving FDA approval for its abbreviated new drug application for Mycobutin rival, Rifabutin capsules for 150mg dose.
ANI Pharmaceuticals has announced receiving the long-awaited FDA approval for its Cortrophin Gel and has plans for a full-scale commercial launch of the product in the first quarter of 2022. Meanwhile, ANI’s $210m acquisition of niche generics specialist Novitium Pharma is expected to close imminently.
Before closing its acquisition of fellow US-based manufacturer Novitium Pharma, ANI Pharmaceuticals must agree to several orders, including divestment of rights and/or assets for two generic products.